Viewing Study NCT06769412

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:09 AM
Ignite Modification Date: 2026-01-13 @ 10:41 PM
Study NCT ID: NCT06769412
Status: COMPLETED
Last Update Posted: 2025-10-29
First Post: 2024-12-24
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
Sponsor: Regeneron Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Retinal Vasculitis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Anti-vascular endothelial growth factor View
None Aflibercept View
None Neovascular age-related macular degeneration (nAMD) View
None Diabetic macular edema (DME) View
None Diabetic retinopathy (DR) without macular edema (ME) View
None Diabetic retinopathy (DR) with macular edema (ME) View